AbbVie's Humira defense may keep prices high, but it's still legal, judge rules

AbbVie reaps billions of dollars annually from its big-selling immunology medicine Humira, and, under deals with biosimilar makers, the drug is likely free from U.S. competition until 2023. A class of purchasers had sued over the company's defense strategy—including its so-called "patent thicket"—but a judge has now sided with AbbVie.